India Myocardial Infarction Market Size, Growth Analysis Report, Forecast to 2027


Posted September 15, 2021 by alfahadkhan2510

India myocardial infarction market is estimated to grow modestly at a CAGR of around 8.9% during the forecast period.

 
India myocardial infarction market is estimated to grow modestly at a CAGR of around 8.9% during the forecast period. The availability of advanced treatment options in India with the increasing per capita healthcare expenditure is supporting the growth of the myocardial infarction market in the country. The government is actively focused on improving healthcare infrastructure in the country due to the growing number of chronic diseases including CVDs. As per the Advance Medical Technology Association, the Indian healthcare industry was around $100 billion in 2016 which is expected to reach $175 billion in 2020. Around 77% of the total industry is accounts from hospitals, followed by pharmaceuticals with 14%, medical devices with 6%, and diagnostics with 3%. The pacemaker is one of the major medical devices contributing to the Indian medical device industry, as around 9.3% of the total revenue of the medical device industry is generating from the pacemaker and hearing aid combined. Most of the patient aids are imported from the US, China, Singapore, Australia, South Korea, and Ireland.

Free Sample Copy @ https://www.omrglobal.com/request-sample/india-myocardial-infarction-market

The market study of the India myocardial infarction market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

A Full Report of India Myocardial Infarction Market is Available at:
https://www.omrglobal.com/industry-reports/india-myocardial-infarction-market

The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into a left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.

The companies which are contributing to the growth of the India myocardial infarction market include AstraZeneca PLC, Bayer AG, Abbott Laboratories Inc., GlaxoSmithKline PLC, Pfizer Inc., Koninklijke Philips N.V., Medtronic PLC, and Merck KGaA. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market.

India Myocardial Infarction Market – Segmentation
by Type
Non-ST-elevation myocardial infarction (NSTEMI)
ST-elevation myocardial infarction (STEMI)
Silent Heart Attacks
by Device
Left Ventricular Assist Device (LVAD)
Pacemaker
Catheters
Implantable Cardioverter-Defibrillator (ICD)
Others (Stent Graft)
by Diagnosis
Electrocardiography (ECG)
Chest X-Ray
Computed Tomography (CT Scan)
Echocardiography
Others (Blood Test)
by Treatment
Medication
Analgesics
Thrombolytic
Antiplatelet Agents
Glycoprotein IIb/IIIa Inhibitors
Others (Beta-Adrenergic Blockers)
Surgery
Angioplasty
Bypass Surgery
Heart Transplant
by End-User
Hospital & Clinics
Ambulatory Surgical Centers
Research Institutes
Company Profiles
Abbott Laboratories Inc.
AstraZeneca PLC
Bayer AG
Boston Scientific Corp.
Bristol-Myers Squibb Co.
Eli Lilly and Co.
GlaxoSmithKline Plc
Johnson & Johnson Services, Inc.
Medtronic PLC
Merck KGaA
Mylan N.V.
Novartis AG
Pfizer Inc.
Siemens AG

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/india-myocardial-infarction-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected] 
Contact no: +91 780-304-0404
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Alfahad khan
Phone +91 780-304-0404
Country India
Categories Business
Tags india myocardial infarction market
Last Updated September 15, 2021